Frederick Alexander, MD
Infectious Disease · Joliet, ILNPI 1730251042
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,265 of the $71,638 with a category attached, or 89.7%. AbbVie accounts for 93.9% of it on its own, with 5 other manufacturers making up the rest. Among infectious disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $436.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$67K
- Merck$4K
- Astellas Pharma US Inc$314
- Kestra Medical Technology Services, Inc.$90
- La Jolla Pharmaceutical Company$18
- Ferring Pharmaceuticals Inc.$13
What the payments were for
- Speaking & faculty fees$64,26590%
- Travel & lodging$2,3813%
- Food & beverage$4,6777%
- Education$3140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 151 | $67,276 |
| Merck | 6 | $3,926 |
| Astellas Pharma US Inc | 4 | $314 |
| Kestra Medical Technology Services, Inc. | 1 | $90 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$71,638 in reported general payments places this provider in the 95th percentile of 368 infectious disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 33 | $40,110 |
| ErtapenemErtapenem Sodium | 43 | $17,327 |
| Vancomycin Hcl | 55 | $10,680 |
| Cefepime Hcl | 28 | $6,400 |
| Doxycycline Hyclate | 241 | $6,164 |
| Cefdinir | 107 | $5,661 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 184 | $3,825 |
| Levofloxacin | 118 | $3,476 |
| Linezolid | 25 | $3,450 |
| Cefadroxil | 90 | $2,538 |
| Doxycycline Monohydrate | 41 | $2,111 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 11 | $1,917 |
| Ciprofloxacin Hcl | 93 | $1,686 |
| CefuroximeCefuroxime Axetil | 42 | $1,426 |
| Meropenem | 12 | $1,208 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Joliet
- Frank PalellaChicago$987K
- Jeffrey ShermanDeerfield$527K
- Catherine CreticosChicago$335K
- Babafemi TaiwoChicago$292K
- Beverly ShaChicago$202K
- Chad ZawitzChicago$193K
- Nancy GlickChicago$186K
- Kamaljit SinghChicago$138K
- Jorge ParadaMaywood$128K
- James SullivanChicago$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.